Drug Profile
Glycopyrrolate - Sunovion Respiratory Development/PARI Pharma
Alternative Names: EP-101; Glycopyrrolate bromide; Lonhala Magnair; SUN-101; SUN-101/eFlow®Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Elevation Pharmaceuticals
- Developer PARI Pharma GmbH; Sunovion Respiratory Development
- Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chronic obstructive pulmonary disease
- Discontinued Asthma
Most Recent Events
- 31 Dec 2023 Withdrawn for Chronic obstructive pulmonary disease in USA (Inhalation), prior to December 2023
- 08 Sep 2021 Discontinued - Phase-II for Asthma in Germany (Inhalation) (Sunovion website, September 2021)
- 17 May 2019 Efficacy and safety data from a phase III GOLDEN-3 and GOLDEN-4 trials in Chronic obstructive pulmonary disease presented at the 115th International Conference of the American Thoracic Society (ATS-2019)